Galectin Therapeutics GALT
NASDAQ GALT
$3.32 -0.11 (-3.21%)
As of: Oct 21, 2026 · 11:38 AM EDT

Galectin Therapeutics (GALT) Receivables - Other (2010)

Updated

Galectin Therapeutics (GALT) recorded Receivables - Other of $234,000 in Q4 2010.

Analysis

Galectin Therapeutics (GALT) Receivables - Other (2010) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn
10 Galectin Therapeutics 216.07 Mn 159.41 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2010 234,000.00
API Access

Galectin Therapeutics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=GALT&period=max&api_key=YOUR_API_KEY